News

Research – TherapeuticsMD (TXMD) – Assumption of Coverage

Health
0 min read

Monday, April 29, 2019

TherapeuticsMD (TXMD)

Can the Early Commercial Success Eradicate the Stock Overhang?

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

  • Assumption of Coverage with Outperform Rating and $13 Price
    Target. 
    We are assuming coverage of TherapeuticsMD with an Outperform rating and Price Target of $13, based on an NPV analysis of the
    pipeline. Three product approvals were granted by the FDA in 2018 providing a
    solid foundation for the company to become a significant player in the
    women’s health space.
  • Strong Player in Women’s Health. Three product approvals granted in 2018 include; i) Imvexxy
    for patients with vulvovaginal atrophy (VVA), ii) Bijuva (estradiol and
    progesterone) to treat vasomot…





    Get full report on Channelchek desktop.



*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.